4-(3-chloroanilino)quinazoline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128872 |
| CHEMBL ID | 329672 |
| SCHEMBL ID | 136003 |
| MeSH ID | M0235759 |
| Synonym |
|---|
| n-(3-chlorophenyl)quinazolin-4-amine |
| 4-anilino quinazoline deriv. 14 |
| chembl329672 , |
| bdbm3263 |
| OPREA1_681561 |
| OPREA1_688366 |
| SR-02000000183 |
| 88404-44-8 |
| AKOS001614894 |
| (3-chlorophenyl)-quinazolin-4-yl-amine |
| 4-quinazolinamine, n-(3-chlorophenyl)- |
| 4-(3-chloroanilino)quinazoline |
| 4-caq |
| n-(3-chlorophenyl)-4-quinazolinamine |
| STL330854 |
| SCHEMBL136003 |
| DTXSID50237026 |
| PD086253 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Acyl-CoA (8-3)-desaturase | Homo sapiens (human) | IC50 (µMol) | 0.0110 | 0.0110 | 0.0110 | 0.0110 | AID1243190 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.5402 | 0.0000 | 0.5369 | 10.0000 | AID1795505; AID1795540; AID1795558; AID1795635; AID320960; AID66596; AID66602; AID69421 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0110 | 0.0030 | 1.1783 | 9.7724 | AID1243190 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0110 | 0.0030 | 0.0787 | 0.3250 | AID1243190 |
| Beta-3 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0110 | 0.0030 | 0.0787 | 0.3250 | AID1243190 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1795540 | Kinase Inhibition Assay from Article 10.1021/jm9503613: \\Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1 | Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. |
| AID1795635 | EGFR assay from Article 10.1016/0968-0896(96)00107-1: \\Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.\\ | 1996 | Bioorganic & medicinal chemistry, Aug, Volume: 4, Issue:8 | Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. |
| AID1795505 | Kinase Inhibition Assay from Article 10.1021/jm00018a008: \\Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibito | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth fa |
| AID1795558 | Kinase Inhibition Assay from Article 10.1021/jm9903949: \\Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase.\\ | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. |
| AID1243190 | Inhibition of liver delta-5 desaturase (unknown origin) | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Design, synthesis, and in vivo activity of novel inhibitors of delta-5 desaturase for the treatment of metabolic syndrome. |
| AID1303326 | Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. |
| AID1303325 | Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. |
| AID320960 | Inhibition of EGFR | 2008 | Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5 | Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. |
| AID66596 | Concentration needed to inhibit the phosphorylation of a 14-residue fragment of phospholipase C-gamma1 by Epidermal growth factor receptor (prepared from human A431 carcinoma cell vesicles by immunoaffinity chromatography) | 1999 | Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26 | Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase. |
| AID66602 | Evaluation of inhibitory activity against phospholipase C-gamma1 phosphorylation by Epidermal growth factor receptor enzyme isolated from A431 cells. | 1995 | Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18 | Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth fa |
| AID69421 | Concentration required to inhibit the phosphorylation of a 14-residue fragment of phospholipase C gamma 1 by Epidermal growth factor receptor from A431 cell vesicles | 1996 | Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1 | Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. |
| AID1303324 | Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11 | Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.42) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||